Sensitivity of Patient Outcomes to Pharmacist Interventions. Part III: Systematic Review and Meta-Analysis in Hyperlipidemia Management
- 29 July 2008
- journal article
- research article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 42 (9), 1195-1207
- https://doi.org/10.1345/aph.1k618
Abstract
Background: Hyperlipidemia increases the risk of cardiovascular diseases, and control is pivotal ror preventing disease complications. Multidisciplinary interventions, including those performed by pharmacists, are important for improving patients’ outcomes. Objective: To quantify the impact of pharmacist interventions in enhancing patients’ outcomes. Methods: TWO reviewers searched International Pharmaceutical Abstracts, MEDLINE, EMBASE, The Cochrane Central Register of Controlled Trials. 3rd Quarter, and Cumulative Index to Nursing and Allied Health Literature (all from inception to July 2007) for pharmacist interventions in hyperlipidemia. Quality was assessed using the Downs-Black scale. Data extracted included the number of patients enrolled; study characteristics; intervention type; and pre- and postintervention measures for low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, total cholesterol, adherence, and quality of life. A random effects meta-analysis combined data. Heterogeneity of effects was tested using χ5 analysis. Publication bias was assessed using funnel plots and the Begg-Mazumdar statistic. Results: Forty-eight studies were found; 23 met inclusion criteria. Study settings included medical clinic/center (n = 12), community pharmacy (n = 8), hospital (n = 2), and patient homes (n = 1). Article quality was good (71% ± 7.0%). Patient education (78%) and medication management (74%) were the most common interventions. Total cholesterol was significantly reduced from baseline (mean ± SD; 34.3 ± 10.3 mg/dL; p < 0.001) and above that for controls (22.0 ± 10.4 mg/dL: p = 0.034). LDL-C was reduced significantly from baseline (32.6 ± 11.3 mg/dL; p = 0.004), but not significantly more than controls (17.5 ± 10.9 mg/dL; p = 0.109). A clinically relevant but not statistically significant reduction in triglycerides was found. No impact on HDL-C levels was found. Patients’ adherence to pharmacotherapeutic regimens and quality of life were considered possibly not sensitive and possibly sensitive to pharmacist interventions, respectively. Conclusions: Total cholesterol is sensitive to pharmacist interventions, while LDL-C and triglyceride levels are possibly sensitive to those interventions. Further research is required for these outcomes.Keywords
This publication has 43 references indexed in Scilit:
- Development and Preliminary Testing of a Patient Decision Aid to Assist Pharmaceutical Care in the Prevention of Cardiovascular DiseasePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2004
- Pharmacist-run lipid management program in rural Alabama.American Journal of Health-System Pharmacy, 2004
- A Comparison of Orlistat Use in a Veteran Population: A Pharmacist-Managed Pharmacotherapy Weight-Loss Clinic versus Standard Medical CareJournal of Pharmacy Technology, 2003
- A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP).Archives of Internal Medicine, 2002
- Goal attainment and maintenance of serum cholesterol level in a pharmacist-coordinated lipid clinic.American Journal of Health-System Pharmacy, 2001
- Effects of Pharmacists' Consultation on Serum Cholesterol Level Using Drug History Notebook or Drug Instruction Sheets for Outpatients with Hypercholesterolemia.Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2001
- The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventionsJournal of Epidemiology and Community Health, 1998
- Cholesterol Screening in a Community PharmacyJournal of the American Pharmaceutical Association, 1996
- Effects of “group detailing” on the prescribing of lipid-lowering drugs: A randomized controlled trial in Swedish primary careJournal of Clinical Epidemiology, 1995
- Hyperlipidaemia in primary care — a randomized controlled trial on treatment information in Sweden: Design and methodologyPharmacoepidemiology and Drug Safety, 1995